Cited by 184Bone health and treatmentsBone health and osteoporosis researchManagement of metastatic bone disease

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Open access

Henry, David, Vadhan-Raj, Saroj, Hirsh, Vera, von Moos, Roger, Hungria, Vania, Costa, Luis, Woll, Penella J, Scagliotti, Giorgio, Smith, Geoffrey, Feng, Amy, Jun, Susie, Dansey, Roger, Yeh, Howard·2014·Supportive Care in Cancer

DOI 10.1007/s00520-013-2022-1

Open this paper in CoChat — free account Open PDF

Abstract

Purpose Bone complications of metastatic disease, including skeletal-related events (SREs), impair patients' functioning and quality of life. In a randomized, phase 3 trial of 1,776 patients with metastases from solid tumors (except breast or prostate) or multiple myeloma, denosumab was non-inferior to zoledronic acid (ZA) in delaying or preventing SREs. This ad hoc analysis reports outcomes in the subgroup of 1,597 patients with solid tumors, excluding patients with multiple myeloma.Methods Patients received monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg, adjusted for creatinine clearance, with calcium and vitamin D supplementation recommended. Endpoints included times to first on-study SRE, first-and-subsequent SREs, and pain worsening.Results Denosumab significantly delayed time to first on-study SRE compared with ZA (HR, 0.81; 95 % CI, 0.68-0.96) and time to first-and-subsequent SREs (RR, 0.85; 95 % CI, 0.72-1.00). Denosumab also significantly delayed time to development of moderate or severe pain (HR, 0.81; 95 % CI, 0.66-1.00), pain worsening (HR, 0.83; 95 % CI, 0.71-0.97), and worsening pain interference in patients with no/mild baseline pain (HR, 0.77; 95 % CI, 0.61-0.96). Adverse event rates were 96 % in both groups. Grade 3 or 4 hypocalcemia, mostly without clinical sequelae, was more frequent in denosumab-treated patients (denosumab 4 %, ZA 2 %). Osteonecrosis of the jaw occurred infrequently (denosumab 0.8 %, ZA 1.1 %).Conclusions Denosumab was more effective in delaying or preventing SREs in patients with bone metastases from solid tumors and also prevented pain progression compared to ZA in this ad hoc analysis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00520-013-2022-1

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mechanisms of Bone Metastasis
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,752
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,489
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Fizazi, K. S., Carducci, M. A., Smith, M. R., Damião, R., Brown, J. E., Karsh, L. I., Milecki, P., Shore, N. D., Rader, M. E., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,974
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Stopeck, A., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K. S., Boer, R. H. D., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,617
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausová, J., Scagliotti, G. V., Sleeboom, H. P., Spencer, A. G., Vadhan‐Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,271
Management of cancer pain
Portenoy, R. K., & Lesage, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01310-0 · Cited by 1,013
Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 872
Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double‐blind, placebo‐controlled trial
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Fred Saad, C., Lipton, A., Cook, R. J., Chen, Y., Smith, M. R., & Coleman, R. E. (2007) · Cancer · doi:10.1002/cncr.22991 · Cited by 664
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Lipton, A., Fizazi, K. S., Stopeck, A., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 592

Show all 23 references

Sorted by citations

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
“In the study of denosumab versus zoledronic acid in patients with advanced cancers, the time extent to which pain interfered with daily life (used as surrogate for QoL) was longer in patients treated with denosumab and with no pain or mild pain interference at baseline [163].”
Background
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“In the study of denosumab versus zoledronic acid in patients with advanced cancers, the time extent to which pain interfered with daily life (used as surrogate for QoL) was longer in patients treated with denosumab and with no pain or mild pain interference at baseline [319].”
Background
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update
Ruggiero, S. L., Dodson, T. B., Aghaloo, T. L., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,209
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S. B., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 575
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R. E., Body, J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 575
“017) [67].”
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
Fugazzola, L., Elisei, R., Führer, D., Jarząb, B., Leboulleux, S., Newbold, K. L., & Smit, J. W. A. (2019) · European Thyroid Journal · doi:10.1159/000502229 · Cited by 296
The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges
Xie, S., Wu, Z., Qi, Y., Wu, B., & Zhu, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111450 · Cited by 209
Bone Metastasis of Breast Cancer
Tahara, R. K., Brewer, T. M., Theriault, R. L., & Ueno, N. T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_7 · Cited by 174
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials
Boquete‐Castro, A., Moreno, G. G., Calvo‐Guirado, J. L., Aguilar‐Salvatierra, A., & Ruiz, R. A. D. (2015) · Clinical Oral Implants Research · doi:10.1111/clr.12556 · Cited by 170
Bisphosphonates in multiple myeloma: an updated network meta-analysis
Mhaskar, R. S., Kumar, A., Miladinović, B., & Djulbegović, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188.pub4 · Cited by 153
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
Limones, Á., Sáez-Alcaide, L., Díaz-Parreño, S., Helm, A., Bornstein, M. M., & Molinero‐Mourelle, P. (2020) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.23324 · Cited by 154
“59 (19-89) Male (66%) Denosumab 120 mg 4 weeks Subcutaneous”
BackgroundInfluential
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Smith, M. R., Coleman, R. E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K. N., Balakumaran, A., Wei, R., Wang, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu519 · Cited by 145
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
von Moos, R., Costa, L., González‐Suárez, E., Terpos, E., Niepel, D., & Body, J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.003 · Cited by 142
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 131
Prostate Cancer in Elderly Men
Roussel, B. N., Ouellet, G. M., Mohile, S. G., & Dale, W. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.07.004 · Cited by 122
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors
Dodson, T. B. (2015) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2015.06.003 · Cited by 120
Bone metastases in thyroid cancer
Iñiguez‐Ariza, N. M., Bible, K. C., & Clarke, B. L. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100282 · Cited by 113
An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma
Grünwald, V., Eberhardt-Wetherington, B., Bex, A., Flörcken, A., Gauler, T. C., Derlin, T., Panzica, M., Dürr, H. R., Grötz, K. A., Giles, R. H., et al. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0034-9 · Cited by 103
Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain
von Moos, R., Costa, L., Ripamonti, C. I., Niepel, D., & Santini, D. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.021 · Cited by 100
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series
Aljohani, S., Gaudin, R., Weiser, J., Troeltzsch, M., Ehrenfeld, M., Kaeppler, G., Smeets, R., & Otto, S. (2018) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2018.05.046 · Cited by 80
A comprehensive review of denosumab for bone metastasis in patients with solid tumors
Gül, G., Şendur, M. A. N., Aksoy, S., Sever, A. R., & Altundağ, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1105795 · Cited by 80
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
von Moos, R., Body, J.-J., Egerdie, B., Stopeck, A., Brown, J. E., Fallowfield, L. J., Patrick, D. L., Cleeland, C. S., Damyanov, D., Palazzo, F. G., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2908-1 · Cited by 79
“jority of patients in the other solid tumors trial had lung cancer (46 %) [23, 24]).”
Background
Chemotherapy- and Irradiation-Induced Bone Loss in Adults with Solid Tumors
Wissing, M. D. (2015) · Current Osteoporosis Reports · doi:10.1007/s11914-015-0266-z · Cited by 73
Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis
Jung, K., & Lein, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.001 · Cited by 73
Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials
Menshawy, A., Mattar, O. M., Abdulkarim, A. N., Kasem, S. A., Nasreldin, N., Menshawy, E., Mohammed, S., Abdel-Maboud, M., Gadelkarim, M., Ashal, G. E., et al. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4060-1 · Cited by 68
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
Cadieux, B., Coleman, R. E., Jafarinasabian, P., Lipton, A., Orlowski, R. Z., Fred Saad, C., Scagliotti, G. V., Shimizu, K., & Stopeck, A. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100416 · Cited by 69
Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures
Pittman, K. B., Antill, Y. C., Goldrick, A., Goh, J. C. H., & Boer, R. H. D. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12517 · Cited by 67
Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials
Chen, F., & Pu, F. (2016) · Oncology Research and Treatment · doi:10.1159/000447372 · Cited by 61
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
Takahashi, M., Ozaki, Y., Kizawa, R., Masuda, J., Sakamaki, K., Kinowaki, K., Umezu, T., Kondoh, C. N., Tanabe, Y., Tamura, N., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6236-6 · Cited by 58
Systematic Literature Review and Network Meta-Analysis Comparing Bone-Targeted Agents for the Prevention of Skeletal-Related Events in Cancer Patients With Bone Metastasis
Wang, Z., Qiao, D., Lu, Y., Curtis, D., Wen, X., Yao, Y., & Zhao, H. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0328 · Cited by 58
SEOM Clinical Guideline for bone metastases from solid tumours (2016)
Grávalos, C., Rodriguez, C. A., Sabino, A., Seguí, M. Á., Virizuela, J. A., Carmona‐Bayonas, A., Cassinello, J., Isla, D., Jara, C., & Martín, M. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1590-1 · Cited by 54
The Roadmap of RANKL/RANK Pathway in Cancer
Casimiro, S., Vilhais, G., Gomes, I., & Costa, L. (2021) · Cells · doi:10.3390/cells10081978 · Cited by 55
“This trial evidenced that denosumab was statically non-inferior in preventing SREs and carried a PFS but not an OS advantage compared with ZA.”
ResultInfluential
Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications
de Castro, J., García, R., Garrido, P., Isla, D., Massutí, B., Blanca, B., & Vázquez, J. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.06.004 · Cited by 53
Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics
Fang, J., & Xu, Q. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1247-x · Cited by 52
Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy
Yang, S. P., Kim, T. W. B., Boland, P. J., & Farooki, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0192 · Cited by 53
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities
Shay, G., Hazlehurst, L., & Lynch, C. C. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1345-4 · Cited by 48
“However, the therapies do significantly delay skeletal-related events such as pathological fracture and therefore importantly reduce disease-associated morbidity [6, 36].”
Background
Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non–Small Cell Lung Cancer and Bone Metastases: A Systematic Review
Hendriks, L. E. L., Hermans, B. C. M., Everdingen, M. H. J. V. D. B.-V., Hochstenbag, M. M. H., & Dingemans, A. C. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.001 · Cited by 50
Bone Metastasis: Current State of Play
Turpin, A., Duterque‐Coquillaud, M., & Vieillard, M.-H. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.10.012 · Cited by 53
Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis
Chen, J., Zhou, L., Liu, X., Wen, X., Li, H., & Li, W. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01105-1 · Cited by 49
Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours
Zheng, G., Chang, B., Lin, F.-X., Xie, D., Hu, Q. X., Guo, Y., Du, S., & Li, X. D. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12541 · Cited by 45
“…enosumab 120 mg SC versus ZA 4 mg IV T ime to first on- study SRE P athological fracture, Spinal cord compression, and radiotherapy or surgery to bone Henry et al. (2014) J une 2006 (34 months) R andomised, double- blind trials V arious solid tumours D enosumab 120 mg SC versus ZA 4 mg IV T ime…”
BackgroundInfluential
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study
Terpos, E., Raje, N. S., Croucher, P. I., García‐Sánz, R., Leleu, X. P., Pasteiner, W., Wang, Y., Glennane, A., Canon, J. R., & Pawlyn, C. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002378 · Cited by 44
Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents
Patrick, D. L., Cleeland, C. S., von Moos, R., Fallowfield, L. J., Wei, R., Öhrling, K., & Qian, Y. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2525-4 · Cited by 42
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
Jiang, L., Cui, X., Ma, H., & Tang, X. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02554-8 · Cited by 38
“[23], the median time to first on-study SRE was 21.”
BackgroundInfluential
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study
Brunner, C., Arvandi, M., Marth, C., Egle, D., Baumgart, F., Emmelheinz, M., Walch, B., Lercher, J., Iannetti, C., Wöll, E., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00171 · Cited by 38
Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials
Seeto, A. H., Abrahamsen, B., Ebeling, P. R., & Rodríguez, A. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4157 · Cited by 36
ecancermedicalscience
Spurrell, E. L., & Lockley, M. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.441 · Cited by 36
Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience
Favia, G., Tempesta, A., Limongelli, L., Crincoli, V., & Maiorano, E. (2016) · International Journal of Dentistry · doi:10.1155/2016/1801676 · Cited by 34
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression
Mondello, P., Cuzzocrea, S., Navarra, M., & Mian, M. (2017) · Oncotarget · doi:10.18632/oncotarget.14610 · Cited by 34
“These therapies significantly delay skeletal-related events such as pathological fracture and therefore reduce disease-associated morbidity [59, 60], and prolong survival [61-63].”
Background
Complications of bone metastases from malignant melanoma
Zekri, J., Marples, M., Taylor, D., Kandukurti, K., McParland, L., & Brown, J. E. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.08.003 · Cited by 34
Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review
Querrer, R., Ferrare, N., de Melo, N. S., Stefani, C. M., dos Reis, P. E. D., Mesquita, C. R. M., Borges, G. Á., Leite, A. F., & Figueiredo, P. T. D. S. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05855-6 · Cited by 33
Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
Yue, J., Sun, W., & Li, S. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100441 · Cited by 29
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients
Owosho, A. A., Blanchard, A., Levi, L., Kadempour, A., Rosenberg, H. I., Yom, S. K., Farooki, A., Fornier, M. N., Huryn, J. M., & Estilo, C. L. (2015) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2015.12.005 · Cited by 28
“Various clinical trials have shown that denosumab may be more effective than zoledronic acid in the prevention of SREs in patients with metastatic bone disease (Stopeck et al., 2010; Henry et al., 2014; Fizazi et al., 2011; Lipton et al., 2012; Scagliotti et al., 2012; Sun and Yu, 2013).”
Background
The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey
Lebrét, T., Casas, A., Cavo, M., Woll, P. J., Deleplace, C., Kennedy, C., Schoen, P., & Jackisch, C. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12490 · Cited by 28
An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain
Danson, S. J., Mulvey, M. R., Turner, L., Horsman, J. M., Escott, K. J., Coleman, R. E., Ahmedzai, S. H., Bennett, M., & Andrew, D. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100261 · Cited by 28
Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis
Lorange, J.-P., Luna, J. R. G., Grou-Boileau, F., Rosenzweig, D. H., Weber, M. H., & Akoury, E. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100470 · Cited by 28
Health resource utilization associated with skeletal-related events: results from a retrospective European study
Body, J., Pereira, J., Sleeboom, H. P., Maniadakis, N., Terpos, E., Acklin, Y. P., Fínek, J., Gunther, O., Hechmati, G., Mossman, T., et al. (2015) · The European Journal of Health Economics · doi:10.1007/s10198-015-0716-7 · Cited by 28
“asymptomatic SREs are often captured by regular examinations, including as bone scanning, used during follow-up [32, 33, 39].”
Background
Effect of agents affecting bone homeostasis on short‐ and long‐term implant failure
Jung, J., Ryu, J., Shim, G., & Kwon, Y. (2023) · Clinical Oral Implants Research · doi:10.1111/clr.14144 · Cited by 28
Bone pain: current and future treatments
Frost, C. Ø., Hansen, R. B., & Heegaard, A. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.007 · Cited by 26
All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma
Brozovich, A., Garmezy, B., Pan, T., Wang, L., Farach‐Carson, M. C., & Satcher, R. L. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100399 · Cited by 25
Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer
da Silva, G. T., Bergmann, A. K., & Thuler, L. C. S. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2835-1 · Cited by 25
“A phase III clinical trial [29] reported that denosumab extended the time to first SRE by a median of 6 months compared to zoledronic acid, resulting in a risk reduction for a first SRE of 19% and in an improvement of pain outcomes in patients with bone metastasis due to solid tumours including NSCLC.”
Background
The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies
Chhichholiya, Y., Suman, P., Singh, S., & Munshi, A. (2021) · Medical Oncology · doi:10.1007/s12032-021-01547-1 · Cited by 22
Mechanistic and therapeutic insights gained from studying rare skeletal diseases
Tosi, L. L., & Warman, M. L. (2015) · Bone · doi:10.1016/j.bone.2015.03.016 · Cited by 24
“zoledronate in delaying the onset of first skeletal-related events [49,50].”
Bone Metastases and Skeletal-Related Events: Incidence and Prognosis According to Histological Subtype of Lung Cancer
da Silva, G. T., Silva, L. M., Bergmann, A. K., & Thuler, L. C. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0613 · Cited by 24
Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
Jacobson, D., Cadieux, B., Higano, C. S., Henry, D. H., Bachmann, B. A., Rehn, M., Stopeck, A., & Saad, H. A. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100423 · Cited by 23
The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone
Hussain, A., Lee, R. J., Graff, J. N., & Halabi, S. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.020 · Cited by 23
“The pivotal phase III trial of denosumab in metastatic lung cancer assessed the time to first on-study SRE as the primary endpoint, demonstrating that denosumab was non-inferior, and there was a trend towards superiority, when compared with zoledronic acid in delaying SREs in a cohort of patients with non-small cell l…”
Background
Do Bisphosphonates Alleviate Pain in Children? A Systematic Review
Celin, M. R., Simon, J. C., Krzak, J. J., Fial, A., Kruger, K. M., Smith, P. A., & Harris, G. F. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00621-3 · Cited by 21
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis
Huang, S., Yoon, S., Shimizu, K., Chng, W. J., Chang, C., Wong, R. S. M., Gao, S., Wang, Y., Gordon, S. W., Glennane, A., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01395-x · Cited by 21
Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia
Alankus, B., Ecker, V., Vahl, N., Braun, M., Weichert, W., Macher-Göppinger, S., Gehring, T., Neumayer, T., Zenz, T., Buchner, M., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200517 · Cited by 20
Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‑analysis
Zhang, C.-R., Shen, G., Li, H., Xin, Y., Shi, M., Zheng, Y., Wang, M., Liu, Z., Zhao, Y. D., Zhao, F., et al. (2023) · Special Care in Dentistry · doi:10.1111/scd.12877 · Cited by 20
Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark
Corraini, P., Heide‐Jørgensen, U., Schiødt, M., Nørholt, S. E., Acquavella, J., Sørensen, H. T., & Ehrenstein, V. (2017) · Cancer Medicine · doi:10.1002/cam4.1173 · Cited by 20
Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge?
Gampenrieder, S. P., Rinnerthaler, G., & Greil, R. (2014) · Breast Care · doi:10.1159/000368710 · Cited by 19
Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report
Kaku, T., Oh, Y., Sato, S., Koyanagi, H., Hirai, T., Yuasa, M., Yoshii, T., Nakagawa, T., Miyaké, S., & Okawa, A. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100301 · Cited by 19
Giant Cell Tumors of the Bone: Changes in Image Features after Denosumab Administration
Oguro, S., Okuda, S., Sugiura, H., Matsumoto, S., Sasaki, A., Susa, M., Morioka, H., & Jinzaki, M. (2018) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.mp.2017-0072 · Cited by 19
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials
Chen, C., Li, R., Yang, T., Ma, L., Zhou, S., Li, M., Zhou, Y. F., & Cui, Y. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.019 · Cited by 18
Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
Jiang, L., Dong, J., Wei, J., & Liu, L. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05997-0 · Cited by 20
Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale
Tyan, A., Patel, S. P., Block, S., Hughes, T. H., & McCowen, K. C. (2019) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2019.02.003 · Cited by 18
Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland
Löthgren, M., Ribnicsek, E., Schmidt, L., Habacher, W., Lundkvist, J., Pfeil, A. M., Biteeva, I., Vrouchou, P., & Bracco, A. (2013) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2012-000235 · Cited by 18
Thymus-derived hormonal and cellular control of cancer
Savino, W., & Lepletier, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168186 · Cited by 17
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic
Cristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1328423 · Cited by 16
“SRE type distribution (pooled across both treatment groups)[13-15] Pathologic fracture 0.”
Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid
Ciobanu, G. A., Camen, A., Ionescu, M., Vlad, D., Munteanu, C. M., Gheorghiță, M., Lungulescu, C. V., Staicu, I. E., Sin, E. C., Chivu, L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113747 · Cited by 15
“3% after three years of administration, being lower than that for denosumab [18].”
Background
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review
Matuoka, J. Y., Kahn, J. G., & Secoli, S. R. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-018-1011-1 · Cited by 14
A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study
Assili, Z., Dolivet, G., Salleron, J., Griffaton-Tallandier, C., Egloff‐Juras, C., & Phulpin, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112390 · Cited by 14
RETRACTED: Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
Li, S., Peng, C., & Yang, Q. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100217 · Cited by 14
Retracted
Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases
Rachner, T. D., Coleman, R. E., Hadji, P., & Hofbauer, L. C. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4391 · Cited by 13
Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Trials
Farii, H. A., Frazer, A., Farahdel, L., Alfayez, S. M., & Weber, M. H. (2019) · Global Spine Journal · doi:10.1177/2192568219884069 · Cited by 12
The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis
Zang, L., Ma, M., Hu, J., Qiu, H., Huang, B. S., & Chu, T. (2015) · Scientific Reports · doi:10.1038/srep18324 · Cited by 12
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)
Duan, J., Fang, W., Xu, H., Wang, J., Chen, Y., Ding, Y., Dong, X., Fan, Y., Gao, B., Hu, J., et al. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.08.004 · Cited by 11
Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review)
Xu, Y., Zhang, G., Liu, Y., Liu, Y., Tian, A., Che, J., & Zhang, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5692 · Cited by 11
Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials
Farii, H. A., Frazer, A., Farahdel, L., AlFayyadh, F. M., & TURCOTTE, R. E. (2020) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-20-00045 · Cited by 11
“Zoledronic acid (IV 4 mg Q4W) 797 130 61 498 (62) 103 (13)”
The first quantitative histomorphological analyses of bone vitality and inflammation in surgical specimens of patients with medication‐related osteonecrosis of the jaw
Mamilos, A., Spoerl, S., Spanier, G., Ettl, T., Brochhausen, C., & Klingelhöffer, C. (2020) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13112 · Cited by 11
Pharmacologic management of metastatic bone disease
Schwartz, E. B., Reichert, Z. R., & Poznak, C. H. V. (2020) · Bone · doi:10.1016/j.bone.2020.115735 · Cited by 11
Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
Brouns, A., van Veelen, A., Veerman, G., Steendam, C. M. J., Dursun, S., van der Leest, C., Croes, S., Dingemans, A. C., & Hendriks, L. E. L. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100513 · Cited by 10
Physician Preferences for Bone Metastasis Drug Therapy in Canada
Pérez-Arellano, J.-L., González, J. M., Qian, Y., Habib, M. B., Mohamed, A. F., Gatta, F., Hauber, B., Posner, J., Califaretti, N., & Chow, E. (2015) · Current Oncology · doi:10.3747/co.22.2380 · Cited by 10
Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw
Thiel, Y., Ghayor, C., Lindhorst, D., Essig, H., Weber, F. E., Rücker, M., & Schumann, P. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153245 · Cited by 10
The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn
Deligiorgi, M. V., & Trafalis, D. T. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1861246 · Cited by 10
Denosumab‐related osteonecrosis of the jaws: successful management with a conservative surgical approach
Póvoa, R. C. D. S., Marlière, D. A. A., da Silveira, H. M., & Pires, F. R. (2016) · Special Care in Dentistry · doi:10.1111/scd.12168 · Cited by 10

Authors: Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., Jun, S., Dansey, R., & Yeh, H.
Affiliations: Pennsylvania Hospital (US)
McGill University Health Centre (CA)
University of Sheffield (GB)
University of Turin (IT)
Amgen (United States) (US)
Corresponding author: Henry, David
ORCID: Henry, David
Woll, Penella J
Scagliotti, Giorgio
Venue: Supportive Care in Cancer
Publisher: Springer Science and Business Media LLC
Published: 2013-10-26
Volume: 22
Issue: 3
Pages: 679-687
ISSN: 0941-4355 (ISSN-L)
1433-7339
DOI: 10.1007/s00520-013-2022-1
OpenAlex: W2066699153
Cited by: 183
References: 23
Citations by year: 2026: 2 · 2025: 11 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 11 · 2020: 21 · 2019: 17 · 2018: 14 · 2017: 10 · 2016: 16 · 2015: 21 · 2014: 16 · 2013: 1
FWCI: 9.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Supportive Care in Cancer (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders: Amgen
Topics: Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords: denosumab, zoledronic acid, skeletal-related events, bone metastasis, solid tumors, bone pain, hypocalcemia, osteonecrosis of the jaw, bisphosphonates, non-inferiority, metastatic cancer
MeSH terms: Denosumab, Zoledronic Acid, Adolescent, Adult, Aged, Aged, 80 and over, Bone Neoplasms, Bone Resorption, Diphosphonates, Double-Blind Method, Female, Humans, Imidazoles, Male, Middle Aged, Multiple Myeloma, Neoplasms, Pain, Treatment Outcome, Disease Progression, Bone Density Conservation Agents, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks